Patents by Inventor Cornelis Van Berkel

Cornelis Van Berkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-IL13R ALPHA2 ANTIBODIES
    Publication number: 20220033508
    Abstract: This disclosure relates to antibodies that specifically bind to the Interleukin-13 receptor subunit alpha-2 (IL13R?2) protein, and associated uses and methods for production.
    Type: Application
    Filed: July 30, 2021
    Publication date: February 3, 2022
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Francois Bertelli
  • COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY-DRUG CONJUGATE
    Publication number: 20220016259
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.
    Type: Application
    Filed: April 20, 2018
    Publication date: January 20, 2022
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Lisa Skelton, Francesca Zammarchi, Jay Marshall Feingold, Jens Wuerthner, John Hartley
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20220016261
    Abstract: The present disclosure relates to pyrrolobenzodiazepines (PBDs) having a labile C2 or N10 protecting group in the form of a linker to an antibody.
    Type: Application
    Filed: July 20, 2021
    Publication date: January 20, 2022
    Inventor: Patricius Hendrikus Cornelis VAN BERKEL
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20220008552
    Abstract: A conjugate of formula (I): Ab-(DL)p??(I) wherein: Ab is an antibody that binds to AXL; DL is
    Type: Application
    Filed: September 24, 2021
    Publication date: January 13, 2022
    Inventor: Patricius Hendrikus Cornelis VAN BERKEL
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 11160872
    Abstract: A conjugate of formula (T): Ab-(DL)p wherein: Ah is an antibody that hinds to AXL; DL is formula (A).
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: November 2, 2021
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventor: Patricius Hendrikus Cornelis Van Berkel
  • Humanized anti-AXL antibodies
    Patent number: 11059893
    Abstract: The present disclosure relates to humanized anti-Axl antibodies.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: July 13, 2021
    Assignee: BERGENBIO ASA
    Inventors: Patricius Hendrikus Cornelis Van Berkel, David G. Williams
  • PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES
    Publication number: 20210137940
    Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.
    Type: Application
    Filed: August 6, 2020
    Publication date: May 13, 2021
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Philip Wilson HOWARD
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20210113587
    Abstract: The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
    Type: Application
    Filed: August 28, 2020
    Publication date: April 22, 2021
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Philip Wilson HOWARD, John HARTLEY
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20210093731
    Abstract: A conjugate of formula (T): Ab-(DL)p wherein: Ah is an antibody that hinds to AXL; DL is formula (A).
    Type: Application
    Filed: February 8, 2018
    Publication date: April 1, 2021
    Inventor: Patricius Hendrikus Cornelis VAN BERKEL
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20210079020
    Abstract: The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.
    Type: Application
    Filed: February 8, 2018
    Publication date: March 18, 2021
    Inventor: Patricius Hendrikus Cornelis VAN BERKEL
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20200405873
    Abstract: The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for in treating disorders characterized by the presence of CD25+ve cells.
    Type: Application
    Filed: March 2, 2020
    Publication date: December 31, 2020
    Inventors: Jay Marshall FEINGOLD, Patricius Hendrikus Cornelis VAN BERKEL
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20200405880
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 31, 2020
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • COMBINATION THERAPY
    Publication number: 20200405879
    Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC), a secondary agent, and optionally an anti-CD20 agent. The Antibody Drug Conjugates target CD19 or CD22 and are disclosed for the treatment of cancers. Methods for identifying an individual as suitable for treatment by selecting patient if he/she is or has been treated with an anti-CD20 agent such as rituximab are disclosed. Optionally, the ADC is administered in combination with a further agent, e.g. a chemotherapeutic agent.
    Type: Application
    Filed: April 20, 2018
    Publication date: December 31, 2020
    Inventors: Jay Marshall Feingold, Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
  • SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES
    Publication number: 20200399365
    Abstract: Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
    Type: Application
    Filed: November 14, 2019
    Publication date: December 24, 2020
    Inventors: Patricius Hendrikus Cornelis VAN BERKEL, Philip Wilson HOWARD
  • PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES
    Publication number: 20200345861
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Application
    Filed: July 21, 2020
    Publication date: November 5, 2020
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 10799596
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: October 13, 2020
    Assignees: ADC THERAPEUTICS S.A., MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES
    Publication number: 20200306385
    Abstract: The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.
    Type: Application
    Filed: May 26, 2020
    Publication date: October 1, 2020
    Inventors: PATRICIUS HENDRIKUS CORNELIS VAN BERKEL, PHILIP WILSON HOWARD
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 10780096
    Abstract: The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: September 22, 2020
    Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
    Inventors: Patricius Henrikus Cornelis Van Berkel, Philip Wilson Howard, John Hartley
  • Pyrrolobenzodiazepine-antibody conjugates
    Patent number: 10780181
    Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: September 22, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard
  • Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
    Patent number: 10751346
    Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: August 25, 2020
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard